Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:43:32.118Z.
Consensus retrieved: 2026-10-06T18:09:03.550Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:43:32.118Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dca1631eda29ddb718d1613c57238547212c9a7381b4d8f04f2ed5a2c46bc485
Forward PE Ratio (N/A) = Dated Quote Price ($3.52) / Consensus Forward EPS ($-1.14)
FORWARD PE RATIO
N/A
Wave Life Sciences Ltd.
Market Cap
$693.61M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Wave Life Sciences Ltd. (WVE) | $693.61M | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $693.19M | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $694.79M | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $691.79M | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $685.49M | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $702.82M | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | N/A |
| Verastem, Inc. (VSTM)vs › | $681.02M | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.65M | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.52, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.14 | $-1.25 – $-0.88 | 13 | n/m |
| 2027-12-31 | $-1.32 | $-1.75 – $-0.92 | 14 | n/m |
| 2028-12-31 | $-1.31 | $-1.95 – $-0.23 | 14 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
